メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
医学部・腎泌尿器外科学
藤田医科大学
医学部
概要
フィンガープリント
ネットワーク
プロファイル
(14)
研究成果
(86)
フィンガープリント
医学部・腎泌尿器外科学が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Acid Phosphatase Prostate Isoenzyme
10%
Adverse Event
15%
Alkaline Phosphatase
13%
Androgen Deprivation Therapy
13%
Androgen Receptor
17%
Antiinfective Agent
13%
Biochemical Recurrence
15%
Biological Marker
14%
Bladder Cancer
30%
Bladder Metastasis
13%
Bleeding
22%
Body Mass Index
15%
Bone Metastasis
18%
Brachytherapy
13%
Bronchogenic Cyst
13%
Cabazitaxel
13%
Cancer Specific Survival
23%
Castration Resistant Prostate Cancer
19%
Clear Cell Renal Cell Carcinoma
43%
Combination Therapy
14%
Computer Assisted Tomography
13%
Continence
47%
Corynebacterium urealyticum
13%
Cystectomy
53%
Dentigerous Cyst
13%
Disease
25%
Disease Exacerbation
15%
Diseases
9%
Endocrine Disease
13%
Enfortumab Vedotin
40%
Exanthem
13%
Extracorporeal
13%
Fournier Gangrene
13%
Function Test
13%
Glomerular Filtration Rate
20%
Ileal Conduit
13%
Ileus
10%
Immune Checkpoint Inhibitor
15%
Immune-Related Adverse Events
13%
Immunoglobulin
14%
Immunotherapy
14%
Infection
13%
Inferior Vena Cava
13%
Inguinal Orchiectomy
13%
Iodine 125
13%
Ipilimumab
17%
Ischemia
15%
Kidney Metastasis
35%
Kidney Tumour
14%
Ligation
13%
Liposarcoma
13%
Long Term Survival
13%
Magnetic Resonance Imaging
17%
Molecularly Targeted Therapy
13%
Multivariate Analysis
23%
Muscle Invasive Bladder Cancer
13%
Neoadjuvant Chemotherapy
26%
Neoplasm
71%
Nephrectomy
15%
Nephroureterectomy
14%
Nivolumab
17%
Olaparib
13%
Oncology
14%
Operation Duration
14%
Oral Function
13%
Overall Survival
63%
P16
13%
Partial Nephrectomy
80%
Pembrolizumab
26%
Physical Examination
13%
Postoperative Ileus
15%
Procollagen
13%
Prognostic Factor
19%
Progression Free Survival
19%
Progressive Disease
13%
Propensity Score Matching
19%
Prostate Adenocarcinoma
13%
Prostate Cancer
100%
Prostate Specific Antigen
25%
Radical Nephrectomy
13%
Recurrence Free Survival
26%
Recurrent Disease
22%
Retroperitoneal Lymph Node Dissection
31%
Retrospective Study
29%
Robot-Assisted Prostatectomy
69%
Spermatic Cord
13%
Surgeon
13%
Surgical Margin
20%
Surgical Technique
12%
Thrombectomy
13%
Transitional Cell Carcinoma
66%
Transurethral Resection
10%
Upper Urinary Tract
13%
Ureter
13%
Urinary Diversion
15%
Urinary System
29%
Urinary Tract
11%
Urine Cytology
14%
Urine Incontinence
20%
Urology
13%
Keyphrases
125I Seed Implantation
13%
Abdominal MRI
13%
Abdominal US
13%
Alanine-serine-cysteine Transporter
13%
Alkaline Phosphatase
13%
Androgen Deprivation Therapy
13%
Androgen Receptor Antagonist
13%
Androgen Receptor Splice Variant
13%
Antitumor Effect
13%
AR-V7
13%
Bladder Cancer
13%
Bladder Eversion
13%
Bladder Metastasis
13%
Blood Test Results
13%
Bone Metastasis
15%
Brentuximab Vedotin
13%
Bronchogenic Cyst
13%
C-X-C Chemokine Receptor Type 4 (CXCR4)
13%
Cancer Patients
13%
Cancer Tissue
13%
Carboxyl Terminus
13%
Clear Cell Renal Cell Carcinoma (ccRCC)
14%
Clinical Outcomes
14%
Collaborative Study
13%
Columnar Epithelium
13%
Combination Therapy
13%
Computed Tomography
13%
Corynebacterium Urealyticum
13%
Cytoreductive Nephrectomy
13%
Deep Ensemble
13%
Disease Effects
13%
Disease Impact
13%
Efficacy Comparison
13%
Encrusted Pyelitis
13%
Endocrine Disorders
13%
Ensemble Machine Learning
13%
Fournier's Gangrene
13%
Function Test
13%
High Complexity
13%
High-grade Prostate Cancer
13%
High-grade Urothelial Carcinoma
13%
Immune Checkpoint Inhibitors
21%
Immune-related Adverse Events
13%
Immuno-oncology
13%
Improved Survival
17%
Infection In Urology
13%
Inferior Vena Cava Thrombectomy
13%
Infiltration
13%
Intracorporeal Ileal Conduit
13%
Intraoperative Navigation
13%
Ipilimumab
20%
Laparoscopic Retroperitoneal Lymph Node Dissection
13%
Liposarcoma
13%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
13%
Metastatic Renal Cell Carcinoma (mRCC)
33%
Metastatic Site
13%
Nerve Sparing
13%
Nivolumab
20%
Nuclear Area
13%
Older Patients
14%
Oncological Outcomes
13%
Oral Function
13%
Outcome Patterns
13%
Overall Response Rate
13%
Partial Nephrectomy
13%
Pembrolizumab
13%
Pentafecta Outcomes
13%
Poor Prognosis
14%
Premature Termination Codon
13%
Prognostic Factors
16%
Prognostic Stratification
13%
Progressive Disease
13%
Propeptide
13%
Prospective multi-institutional Study
13%
Prostate Cancer
26%
Prostate Cancer Outcomes
13%
Prostate-specific Antigen Response
13%
Pseudostratified
13%
Rash
13%
Real-world Application
13%
Regulatory T Cells
13%
Renal Cell Carcinoma
13%
Renal Hilar Tumor
13%
Resistance to Immunotherapy
13%
Retroperitoneal Bronchogenic Cyst
13%
Retroperitoneal Mass
13%
Robot-assisted Radical Nephrectomy
13%
Robot-assisted Radical Prostatectomy
13%
Secondary Bladder Cancer
13%
Selective Clamping
13%
Spermatic Cord
13%
Stripping Technique
13%
Subnormothermic
13%
Testicular Epidermoid Cyst
13%
Treg
12%
Type I Procollagen
13%
Tyrosine Kinase Inhibitor
16%
Upper Tract Urothelial Carcinoma
13%
Urethral Suspension
13%
Voided Urine Cytology
13%
Pharmacology, Toxicology and Pharmaceutical Science
Acid Phosphatase Prostate Isoenzyme
10%
Adverse Event
30%
Androgen Receptor
15%
Antibiotic Prophylaxis
8%
Biochemical Recurrence
13%
Biological Marker
17%
Bladder Cancer
31%
Brain Disease
13%
Branched Chain Amino Acid
8%
Cabazitaxel
26%
Cancer Specific Survival
5%
Castration Resistant Prostate Cancer
40%
Chemotherapy
13%
Combination Therapy
15%
Disease
17%
Disease Exacerbation
16%
Diseases
14%
Docetaxel
16%
Dysbiosis
13%
Endocrine Disease
13%
Enfortumab Vedotin
26%
Enterobacter
8%
Enterococcus
8%
Frailty
13%
Heat Shock Protein 27
13%
Ileum
8%
Immune Checkpoint Inhibitor
27%
Immunoglobulin
14%
Immunotherapy
42%
Indoleamine 2,3 Dioxygenase
9%
Ipilimumab
23%
Kidney Metastasis
68%
Kynurenine
5%
Liver Metastasis
6%
Malignant Neoplasm
17%
Metastatic Colorectal Cancer
13%
Microflora
8%
Muscle Invasive Bladder Cancer
13%
Neoplasm
26%
Nivolumab
23%
Olaparib
13%
Overall Survival
47%
Pembrolizumab
26%
Progression Free Survival
29%
Prostate Cancer
42%
Prostate Specific Antigen
20%
Protein Tyrosine Kinase Inhibitor
20%
Racemase
13%
Rash
13%
Recurrence Free Survival
5%
Recurrence Risk
13%
Recurrent Disease
8%
Renal Cell Carcinoma
53%
Transitional Cell Carcinoma
26%
Tryptophan 2,3 Dioxygenase
13%